News

" Using our DCF model and a calculated WACC of 6,9 %, we determine a fair value of CZK 300 and a 12-month price target of CZK 321, " notes Dr. Kalliwoda Research GmbH in analytical report GEVORKYAN, a.s. Initiation of Coverage H1 2025, dated November 10, 2025.   GEVORKYAN, a.s.  announces an update of the independent analyst coverage of its shares.   Dr. Kalliwoda Research has published its analysis  based on strong results for the first half of 2025, which were announced on

" Gevorkyan: Sustained Growth and Strong Margins Amid Expansion and ESG Investments" writes Miroslav Gáfrik. We are pleased to give an update on independent analyst coverage of GEVORKYAN shares. Gafrik Research reinstated its coverage of GEVORKYAN shares and published its report following comany’s strong 1H 2025 results disclosed on 17 September 2025: Gevorkyan: Sustained Growth and Strong Margins Amid Expansion and ESG Investments Gafrik Research is an independent analytics

GEVORKYAN, a.s. («GEVORKYAN»), a leading innovator in powder metallurgy, today confirms that the company will release its selected...

GEVORKYAN invites the company's investors to an online call to present Q2/2025 financial results, taking place on Wednesday, September...

The share buyback programme for employees was approved at the Annual General Meeting held on December 10, 2024.   Following approval,...

Strategic decisions of GEVORKYAN, a.s. taken at the General Meeting 20.6.2025 in Bratislava   In line with the long-term growth strategy,...

19.5.2025: GEVORKYAN, a.s. publishes new documents for the 2025 General Assembly: The total number of shares and...

Revenue increased by 11% to EUR 21 million and EBITDA surpassed EUR 8 million, representing a 39,99% margin. GEVORKYAN, a.s. a...